Orion Pharma Limited (DSE:ORIONPHARM)
Bangladesh
· Delayed Price · Currency is BDT 32.60
+1.70 (5.50%)
At close: Feb 27, 2025
Orion Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 7,383 | 10,621 | 13,927 | 9,662 | 10,833 | 7,648 | Upgrade
|
| Revenue Growth (YoY) | -37.22% | -23.74% | 44.14% | -10.81% | 41.64% | -12.15% | Upgrade
|
| Cost of Revenue | 5,491 | 8,348 | 11,652 | 7,693 | 8,198 | 5,075 | Upgrade
|
| Gross Profit | 1,892 | 2,273 | 2,275 | 1,969 | 2,635 | 2,573 | Upgrade
|
| Selling, General & Admin | 1,228 | 1,344 | 1,282 | 1,294 | 1,138 | 1,026 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -41.7 | -5.44 | Upgrade
|
| Operating Expenses | 1,228 | 1,344 | 1,282 | 1,294 | 1,096 | 1,021 | Upgrade
|
| Operating Income | 664.15 | 929.02 | 992.96 | 675.12 | 1,538 | 1,552 | Upgrade
|
| Interest Expense | -525.5 | -393.38 | -148.29 | -173.23 | -223.43 | -717.01 | Upgrade
|
| Interest & Investment Income | 7.42 | 5.07 | 3.31 | 638.31 | 3.19 | 33.79 | Upgrade
|
| Earnings From Equity Investments | 9.08 | 9.21 | 9.13 | 9.3 | 6.07 | 6.47 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.71 | 0.71 | 0.89 | 0.62 | 1.23 | 1.71 | Upgrade
|
| Other Non Operating Income (Expenses) | -17.26 | -14.75 | -16.91 | -86.74 | -131.51 | -75.22 | Upgrade
|
| EBT Excluding Unusual Items | 138.61 | 535.89 | 841.09 | 1,063 | 1,194 | 801.85 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.82 | -2.86 | 0.21 | 0.08 | -5.93 | -0.05 | Upgrade
|
| Pretax Income | 135.78 | 533.03 | 841.3 | 1,063 | 1,193 | 802 | Upgrade
|
| Income Tax Expense | 178.27 | 181.26 | 147.07 | 172.71 | 68.51 | 64.95 | Upgrade
|
| Earnings From Continuing Operations | -42.48 | 351.77 | 694.23 | 890.75 | 1,125 | 737.05 | Upgrade
|
| Minority Interest in Earnings | 26.49 | -33.65 | -53.29 | -44.67 | -185.68 | -71.36 | Upgrade
|
| Net Income | -16 | 318.12 | 640.94 | 846.08 | 939.06 | 665.69 | Upgrade
|
| Net Income to Common | -16 | 318.12 | 640.94 | 846.08 | 939.06 | 665.69 | Upgrade
|
| Net Income Growth | - | -50.37% | -24.25% | -9.90% | 41.07% | -24.56% | Upgrade
|
| Shares Outstanding (Basic) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| Shares Outstanding (Diluted) | 234 | 234 | 234 | 234 | 234 | 234 | Upgrade
|
| EPS (Basic) | -0.07 | 1.36 | 2.74 | 3.62 | 4.01 | 2.84 | Upgrade
|
| EPS (Diluted) | -0.07 | 1.36 | 2.74 | 3.62 | 4.01 | 2.84 | Upgrade
|
| EPS Growth | - | -50.37% | -24.25% | -9.90% | 41.07% | -24.56% | Upgrade
|
| Free Cash Flow | -74.94 | -289.06 | -1,366 | -1,505 | -1,685 | 338.88 | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -1.24 | -5.84 | -6.43 | -7.20 | 1.45 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.200 | 1.000 | Upgrade
|
| Dividend Growth | 0% | 0% | 0% | -16.67% | 20.00% | -33.33% | Upgrade
|
| Gross Margin | 25.63% | 21.40% | 16.33% | 20.38% | 24.32% | 33.64% | Upgrade
|
| Operating Margin | 9.00% | 8.75% | 7.13% | 6.99% | 14.20% | 20.30% | Upgrade
|
| Profit Margin | -0.22% | 3.00% | 4.60% | 8.76% | 8.67% | 8.70% | Upgrade
|
| Free Cash Flow Margin | -1.02% | -2.72% | -9.81% | -15.58% | -15.56% | 4.43% | Upgrade
|
| EBITDA | 991.87 | 1,500 | 1,574 | 1,148 | 2,529 | 2,461 | Upgrade
|
| EBITDA Margin | 13.44% | 14.12% | 11.30% | 11.88% | 23.34% | 32.19% | Upgrade
|
| D&A For EBITDA | 327.72 | 570.84 | 580.89 | 472.83 | 990.2 | 909.36 | Upgrade
|
| EBIT | 664.15 | 929.02 | 992.96 | 675.12 | 1,538 | 1,552 | Upgrade
|
| EBIT Margin | 9.00% | 8.75% | 7.13% | 6.99% | 14.20% | 20.29% | Upgrade
|
| Effective Tax Rate | 131.29% | 34.01% | 17.48% | 16.24% | 5.74% | 8.10% | Upgrade
|
| Advertising Expenses | - | 26.24 | 20.53 | 19.65 | 21.74 | 26.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.